Tyler Dylan-Hyde Sells 38,000 Shares of Crispr Therapeutics AG (CRSP) Stock

Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 38,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $21.64, for a total transaction of $822,320.00. Following the completion of the sale, the insider now owns 70,204 shares of the company’s stock, valued at $1,519,214.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tyler Dylan-Hyde also recently made the following trade(s):

  • On Friday, December 28th, Tyler Dylan-Hyde sold 700 shares of Crispr Therapeutics stock. The stock was sold at an average price of $21.75, for a total transaction of $15,225.00.
  • On Friday, December 29th, Tyler Dylan-Hyde sold 31,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $22.72, for a total transaction of $704,320.00.
  • On Friday, December 22nd, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $20.55, for a total transaction of $308,250.00.
  • On Friday, December 15th, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.90, for a total transaction of $283,500.00.

Shares of Crispr Therapeutics AG (NASDAQ CRSP) traded up $0.39 during mid-day trading on Thursday, reaching $23.91. 708,409 shares of the company were exchanged, compared to its average volume of 998,167. Crispr Therapeutics AG has a fifty-two week low of $11.63 and a fifty-two week high of $27.39. The company has a market capitalization of $987.75 and a price-to-earnings ratio of -74.72.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The business had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company’s quarterly revenue was up 54.2% compared to the same quarter last year. During the same period last year, the firm earned ($2.77) EPS. analysts expect that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.

A number of equities analysts recently issued reports on CRSP shares. Barclays reaffirmed a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a research report on Friday, September 8th. Cann reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. SunTrust Banks reaffirmed a “hold” rating and set a $16.00 target price on shares of Crispr Therapeutics in a research report on Friday, November 10th. BidaskClub lowered shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Finally, Oppenheimer started coverage on shares of Crispr Therapeutics in a research report on Thursday, December 7th. They set a “hold” rating on the stock. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $22.38.

Institutional investors have recently made changes to their positions in the business. Hershey Trust Co. bought a new stake in Crispr Therapeutics in the 3rd quarter valued at $768,000. Tiff Advisory Services Inc. bought a new stake in Crispr Therapeutics in the 3rd quarter valued at $505,000. Adams Street Partners LLC bought a new stake in Crispr Therapeutics in the 3rd quarter valued at $1,019,000. Granahan Investment Management Inc. MA increased its holdings in Crispr Therapeutics by 51.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after buying an additional 89,839 shares during the period. Finally, Allianz Asset Management GmbH bought a new stake in Crispr Therapeutics in the 3rd quarter valued at $2,384,000. 24.52% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Tyler Dylan-Hyde Sells 38,000 Shares of Crispr Therapeutics AG (CRSP) Stock” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/04/tyler-dylan-hyde-sells-38000-shares-of-crispr-therapeutics-ag-crsp-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply